CAS 1206170-62-8

Formel: C17H20N6O

InChl: InChI=1S/C17H20N6O/c1-17(2,3)23-16-12(9-18)13(19)8-14(22-16)21-11-6-4-10(5-7-11)15(20)24/h4-8H,1-3H3,(H2,20,24)(H4,19,21,22,23)

InChI Key: XDEFNAWAKYQBQY-UHFFFAOYSA-N

SMILES: CC(C)(C)NC1=C(C(=CC(=N1)NC2=CC=C(C=C2)C(=O)N)N)C#N

4-[[4-Amino-5-cyano-6-[(1,1-dimethylethyl)amino]-2-pyridinyl]amino]benzamide

CAS: 1206170-62-8

4-[[4-Amino-5-cyano-6-[(1,1-dimethylethyl)amino]-2-pyridinyl]amino]benzamide

Formel: C₁₇H₂₀N₆O

Reinheit: ≥99%

Molekulargewicht: 324.38

Ref: 54-OR1115953

4-[[4-Amino-5-cyano-6-[(1,1-dimethylethyl)amino]-2-pyridinyl]amino]benzamide

CAS: 1206170-62-8

Reinheit: 99%

Ref: IN-DA01ENNQ

TC-Mps1-12

CAS: 1206170-62-8

TC-Mps1-12 is an effective and selective inhibitor of monopolar spindle 1 (IC50: 6.4 nM) .

Formel: C₁₇H₂₀N₆O

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 324.38

Ref: TM-T17007

TC-Mps1-12

CAS: 1206170-62-8

TC-Mps1-12 is a drug target for skin cancer and bladder cancer. TC-Mps1-12 inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and its downstream signalling cascades, which are involved in cell proliferation. This drug has been shown to be effective in decreasing tumour size in mice with skin cancer. TC-Mps1-12 also inhibits the EGFR downstream signalling pathways in bladder cancer cells, leading to decreased production of inflammatory cytokines and increased apoptosis.

Formel: C₁₇H₂₀N₆O

Reinheit: Min. 95%

Molekulargewicht: 324.38 g/mol

Ref: 3D-GYB17062